Neil B. Minkoff, MD: Dr Hummers, please share the prevalence of chronic fibrosis ILD [interstitial lung disease] with the progressive phenotype? Laura Hummers, MD: It’s tricky to determine a phenotype ...
Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback